ZA202207188B - Liquid tasimelteon formulations and methods of use thereof - Google Patents
Liquid tasimelteon formulations and methods of use thereofInfo
- Publication number
- ZA202207188B ZA202207188B ZA2022/07188A ZA202207188A ZA202207188B ZA 202207188 B ZA202207188 B ZA 202207188B ZA 2022/07188 A ZA2022/07188 A ZA 2022/07188A ZA 202207188 A ZA202207188 A ZA 202207188A ZA 202207188 B ZA202207188 B ZA 202207188B
- Authority
- ZA
- South Africa
- Prior art keywords
- tasimelteon
- formulations
- methods
- liquid
- tasimelteon formulations
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000007788 liquid Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- PTOIAAWZLUQTIO-GXFFZTMASA-N tasimelteon Chemical compound CCC(=O)NC[C@@H]1C[C@H]1C1=CC=CC2=C1CCO2 PTOIAAWZLUQTIO-GXFFZTMASA-N 0.000 title 1
- 229960000660 tasimelteon Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962947774P | 2019-12-13 | 2019-12-13 | |
| US202062972902P | 2020-02-11 | 2020-02-11 | |
| US202063119488P | 2020-11-30 | 2020-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202207188B true ZA202207188B (en) | 2022-08-31 |
Family
ID=73856392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2022/07188A ZA202207188B (en) | 2019-12-13 | 2022-06-29 | Liquid tasimelteon formulations and methods of use thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US11202770B2 (enExample) |
| EP (1) | EP4072542A1 (enExample) |
| JP (3) | JP7503632B2 (enExample) |
| KR (1) | KR102650321B1 (enExample) |
| CN (1) | CN114727978A (enExample) |
| AU (3) | AU2020400065B2 (enExample) |
| CA (1) | CA3161975A1 (enExample) |
| CL (1) | CL2022001546A1 (enExample) |
| CO (1) | CO2022009691A2 (enExample) |
| IL (2) | IL292492A (enExample) |
| MX (2) | MX2022006577A (enExample) |
| NZ (1) | NZ811397A (enExample) |
| WO (1) | WO2021119456A1 (enExample) |
| ZA (1) | ZA202207188B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101587394B1 (ko) * | 2006-05-22 | 2016-01-21 | 반다 파마슈티칼즈, 인코퍼레이티드. | 멜라토닌 효능제 치료 |
| CN106604726A (zh) * | 2014-09-02 | 2017-04-26 | 万达制药公司 | 用于治疗史密斯‑马吉利综合征的他司美琼 |
| NZ811397A (en) * | 2019-12-13 | 2025-11-28 | Vanda Pharmaceuticals Inc | Liquid tasimelteon formulations and methods of use thereof |
| AU2022345260A1 (en) | 2021-09-14 | 2024-04-04 | Vanda Pharmaceuticals Inc. | Treatment of sleep disturbances in autism spectrum disorder patients |
| WO2024258786A1 (en) | 2023-06-12 | 2024-12-19 | Vanda Pharmaceuticals Inc. | Tasimelteon for use in the treatment of delayed sleep-wake phase disorder |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100499106B1 (ko) * | 1996-12-10 | 2005-07-01 | 브리스톨-마이어즈 스퀴브 컴페니 | 벤조디옥솔, 벤조퓨란, 디히드로벤조퓨란, 및 벤조디옥산 멜라토닌 작용제 |
| US20050137247A1 (en) * | 2003-12-22 | 2005-06-23 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of hypertension |
| KR101587394B1 (ko) | 2006-05-22 | 2016-01-21 | 반다 파마슈티칼즈, 인코퍼레이티드. | 멜라토닌 효능제 치료 |
| US20080260837A1 (en) * | 2007-04-20 | 2008-10-23 | Qpharma, L.L.C. | Physically stable aqueous suspensions of active pharmaceuticals |
| WO2011112167A1 (en) * | 2009-03-13 | 2011-09-15 | Reset Therapeutics, Inc. | Compositions and methods for diabetes treatment |
| WO2011009102A1 (en) | 2009-07-16 | 2011-01-20 | Vanda Pharmaceuticals Inc. | Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia |
| IL330095A (en) | 2012-01-26 | 2026-08-01 | Vanda Pharmaceuticals Inc | Tesimalta for use in the treatment of asynchronous circadian rhythm of cortisol |
| CN102675268A (zh) | 2012-05-18 | 2012-09-19 | 济南志合医药科技有限公司 | 制备（1r，2r）-2-（2,3-二氢苯并呋喃-4-基）环丙甲胺的方法 |
| IL266159B2 (en) | 2012-12-18 | 2024-07-01 | Vanda Pharmaceuticals Inc | Treatment of circadian rhythm disorders |
| US10376487B2 (en) | 2013-11-12 | 2019-08-13 | Vanda Pharmaceuticals Inc. | Method of treatment |
| JP6921534B2 (ja) | 2014-02-12 | 2021-08-18 | バンダ・ファーマシューティカルズ・インコーポレイテッドＶａｎｄａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | 高純度医薬品等級タシメルテオン |
| CN106604726A (zh) | 2014-09-02 | 2017-04-26 | 万达制药公司 | 用于治疗史密斯‑马吉利综合征的他司美琼 |
| CN106542973B (zh) * | 2015-09-16 | 2019-06-25 | 南京华威医药科技集团有限公司 | 他司美琼中间体及其制备方法 |
| WO2017059877A1 (en) | 2015-10-07 | 2017-04-13 | Rontis Hellas S.A. | Pharmaceutical composition containing agomelatine and process for the preparation thereof |
| US9944616B2 (en) * | 2016-06-08 | 2018-04-17 | Apotex Inc. | Processes for the preparation of Tasimelteon and intermediates thereof |
| NZ811397A (en) * | 2019-12-13 | 2025-11-28 | Vanda Pharmaceuticals Inc | Liquid tasimelteon formulations and methods of use thereof |
-
2020
- 2020-12-11 NZ NZ811397A patent/NZ811397A/en unknown
- 2020-12-11 US US17/119,953 patent/US11202770B2/en active Active
- 2020-12-11 MX MX2022006577A patent/MX2022006577A/es unknown
- 2020-12-11 EP EP20828508.0A patent/EP4072542A1/en active Pending
- 2020-12-11 KR KR1020227022807A patent/KR102650321B1/ko active Active
- 2020-12-11 IL IL292492A patent/IL292492A/en unknown
- 2020-12-11 JP JP2022535961A patent/JP7503632B2/ja active Active
- 2020-12-11 CA CA3161975A patent/CA3161975A1/en active Pending
- 2020-12-11 IL IL317244A patent/IL317244A/en unknown
- 2020-12-11 CN CN202080081114.7A patent/CN114727978A/zh active Pending
- 2020-12-11 AU AU2020400065A patent/AU2020400065B2/en active Active
- 2020-12-11 WO PCT/US2020/064555 patent/WO2021119456A1/en not_active Ceased
-
2021
- 2021-03-29 US US17/216,427 patent/US11759446B2/en active Active
-
2022
- 2022-05-31 MX MX2026003536A patent/MX2026003536A/es unknown
- 2022-06-09 CL CL2022001546A patent/CL2022001546A1/es unknown
- 2022-06-29 ZA ZA2022/07188A patent/ZA202207188B/en unknown
- 2022-07-11 CO CONC2022/0009691A patent/CO2022009691A2/es unknown
-
2023
- 2023-07-31 US US18/362,194 patent/US12440470B2/en active Active
-
2024
- 2024-04-12 JP JP2024064780A patent/JP7875899B2/ja active Active
- 2024-11-14 US US18/947,694 patent/US12447141B2/en active Active
-
2025
- 2025-07-15 AU AU2025205489A patent/AU2025205489B2/en active Active
- 2025-09-19 US US19/333,661 patent/US20260007633A1/en active Pending
-
2026
- 2026-03-31 AU AU2026202446A patent/AU2026202446A1/en active Pending
- 2026-04-02 JP JP2026061286A patent/JP2026117039A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287720A (en) | modulators of thr-in the cell and methods of using them | |
| IL277889A (en) | Preparations of oligonucleotides and methods of using them | |
| SG11202010131QA (en) | Oligonucleotide compositions and methods of use thereof | |
| LT3983064T (lt) | Cot moduliatoriai ir jų panaudojimo būdai | |
| IL276135A (en) | Preparations and methods of use | |
| IL283387A (en) | Diarylhydantoin compounds and methods of use thereof | |
| IL285928A (en) | Fulvestrant formulations and methods of using them | |
| ZA202100780B (en) | Bismuth-thiol compositions and methods of use | |
| PT3840837T (pt) | Inibidores de arginase e métodos de uso dos mesmos | |
| ZA202000502B (en) | Cosmetic compositions and methods of use | |
| IL280000A (en) | Formulations for reducing tumors and methods of using them | |
| EP3749691A4 (en) | ANGPTL8 LIAISON AGENTS AND THEIR METHODS OF USE | |
| GB2589398B (en) | Compounds and methods of use | |
| IL276053A (en) | Therapeutic Gard and methods of its use | |
| IL284689A (en) | Endoscopic device and methods of its use | |
| IL274433A (en) | Fulvestrant formulations and methods of using them | |
| ZA201905343B (en) | Antiseptic composition comprising polyvinylpyrrolidone and unithiol and use of the composition | |
| GB202009592D0 (en) | Formulations of tie-2 activators and methods of use thereof | |
| IL278575B1 (en) | Dantrolene formulations and methods of using them | |
| GB2597210B (en) | Breaker fluids and methods of use thereof | |
| ZA202007107B (en) | Compositions comprising pcsk9-binding molecules and methods of use | |
| EP3595776A4 (en) | FLUTICASONE SUSTAINED-RELEASE FORMULATIONS AND THEIR PROCEDURES FOR USE | |
| IL290548A (en) | Bacteria and methods of use thereof | |
| IL289073A (en) | Dichlorphenamide compositions and methods of use | |
| HK40045754A (en) | B7-h7-binding agents and methods of use thereof |